MarketPulse

HbA1c reduction

3 articles
BenzingaBenzinga··Vandana Singh

Novo Nordisk Advances Oral GLP-1 Therapy for Young Diabetics

Novo Nordisk reports positive phase 3a trial results for oral semaglutide in children with type 2 diabetes, planning 2026 regulatory filings for potential first pediatric GLP-1 approval.
NVOregulatory approvalOzempic
GlobeNewswire Inc.GlobeNewswire Inc.··Novo Nordisk A/S

Novo Nordisk's Awiqli Wins FDA Approval as First Once-Weekly Basal Insulin for Type 2 Diabetes

FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin for type 2 diabetes, launching in US during second half 2026 based on successful ONWARDS trials.
NVOFDA approvalType 2 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Biomea Fusion, Inc.

Biomea Fusion's Diabetes Drug Shows Durable Benefits Nine Months Post-Dose

Biomea Fusion presents positive Phase II data for icovamenib in type 2 diabetes, showing durable 1.2% HbA1c reduction nine months after dosing with favorable safety profile.
BMEAobesityType 2 diabetes